Avricore Health Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Avricore Health Inc (VANC) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Avricore Health Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 3M vs 3,880M combined for tracked competitors (0.1% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months), vs accelerating (+13.0%) for its tracked peer group.
- Growth: Avricore Health Inc generated 79.0% revenue growth year over year in Q4 2024, vs 30.5% for its tracked competitors combined.
- Profitability: Its -14.9% net margin compares with 11.9% for the peer group.
- Peer revenue share: Avricore Health Inc accounted for 0.3% of combined revenue among its tracked peer group, up from 0.2% a year earlier.
- Peer differentiation: Revenue per employee of $0.29M compares with $0.72M for the peer group (0.4x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
VANC Sales vs. its Competitors, Q4 2024
Avricore Health Inc reported revenue growth of 79.01 % year on year in Q4 2024, above its competitors' combined revenue growth of 30.54 %.
With a net margin of -14.90 %, Avricore Health Inc reported lower profitability than its competitors (11.91 %).
Avricore Health Inc generated 0.31 % of the combined sales of its peer group, up from 0.23 % a year earlier.
Avricore Health Inc vs. its Competitors, Q4 2024
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Avricore Health Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Avricore Health Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Avricore Health Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 7.2% year over year, combined, vs 79.0% for Avricore Health Inc. Avricore Health Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Avricore Health Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Avricore Health Inc | - | - | - | - |
| Competitors combined (6) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
VANC Stock Performance relative to its Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Boundless Bio Inc | 282.9% | Outperformed |
| 2 | Neurogene Inc | 282.9% | Outperformed |
| 3 | Gentherm Incorporated | 282.9% | Outperformed |
| 4 | Sarepta Therapeutics Inc | 282.9% | Outperformed |
| 5 | Fulgent Genetics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Avricore Health Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Avricore Health Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Avricore Health Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Avricore Health Inc | - | 3.44 |
| Sarepta Therapeutics Inc | 1,982.10 | 1,974.34 |
| Gentherm Incorporated | 1,043.72 | 1,578.33 |
| Neurogene Inc | 642.28 | - |
| Fulgent Genetics Inc | 626.19 | 322.97 |
| Boundless Bio Inc | 58.59 | - |
| SUBTOTAL | 4,380.17 | 3,883.17 |
Sign in to see all competitors of Avricore Health Inc .
Sources: Avricore Health Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Avricore Health Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Avricore Health Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Sarepta Therapeutics Inc | All Other Segments 100.00 % |
| Gentherm Incorporated | Automotive Segments 97.27 % |
| Fulgent Genetics Inc | Precision Diagnostics 57.08 % |
| Biolargo Inc | BioLargo Engineering Science Technologies LLC 87.34 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Avricore Health Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Avricore Health Inc | - | 286,692 | -42,703 |
| Sarepta Therapeutics Inc | 1,982 | 2,364,484 | -8,798 |
| Gentherm Incorporated | 1,044 | 526,110 | 8,858 |
| Neurogene Inc | 642 | - | -848,168 |
| Fulgent Genetics Inc | 626 | 240,307 | -63,593 |
| Boundless Bio Inc | 59 | - | -2,286,143 |
| PEERS TOTAL | 4,380 | 720,603 | -48,320 |
Sign in to see all peers for Avricore Health Inc .
Avricore Health Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Gentherm Incorporated | Non Us 68.03 % |
| Fulgent Genetics Inc | Other countries 4.93 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Avricore Health Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
Weaknesses
No rule matched.
Opportunities
- A meaningful share of tracked competitors (83.30 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Avricore Health Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Avricore Health Inc | 0.87 | 1.21 | - |
| Sarepta Therapeutics Inc | 0.81 | 3.24 | 0.48 |
| Gentherm Incorporated | 0.43 | 1.98 | 0.54 |
| Neurogene Inc | 5.76 | 14.24 | - |
| Fulgent Genetics Inc | 0.68 | 6.24 | 0.00 |
| Boundless Bio Inc | 2.96 | 9.54 | - |
Sign in to see all peers for Avricore Health Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Avricore Health Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Avricore Health Inc | Q4 2024 | +79.0 % | - |
| Sarepta Therapeutics Inc | Q2 2026 | -34.3 % | - |
| Gentherm Incorporated | Q2 2026 | +11.0 % | +826.6 % |
| Neurogene Inc | Q2 2026 | - | - |
| Fulgent Genetics Inc | Q2 2026 | +4.9 % | - |
| Boundless Bio Inc | Q2 2026 | - | - |
| PEERS TOTAL | -15.3 % | - |
Sign in to see all peers for Avricore Health Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Avricore Health Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Avricore Health Inc | Q4 2024 | +27.3 % | -82.3 % |
| Sarepta Therapeutics Inc | Q2 2026 | - | -98.3 % |
| Gentherm Incorporated | Q2 2026 | +12.2 % | -3.4 % |
| Neurogene Inc | Q2 2026 | - | +139.2 % |
| Fulgent Genetics Inc | Q2 2026 | +27.0 % | -43.5 % |
| Boundless Bio Inc | Q2 2026 | - | -20.8 % |
Sign in to see all peers for Avricore Health Inc .
Avricore Health Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Avricore Health Inc | - | - | - |
| Sarepta Therapeutics Inc | - | - | - |
| Gentherm Incorporated | 1.86% | 2.26% | 3.69% |
| Neurogene Inc | - | - | - |
| Fulgent Genetics Inc | - | - | - |
| Boundless Bio Inc | - | - | - |
Sign in to see all peers for Avricore Health Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Avricore Health Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Avricore Health Inc | - | - |
| Sarepta Therapeutics Inc | - | 1.00 |
| Gentherm Incorporated | 43.65 | 0.66 |
| Neurogene Inc | - | - |
| Fulgent Genetics Inc | - | 1.94 |
| Boundless Bio Inc | - | - |
| PEERS AVERAGE | - | 1.13 |
Sign in to see all peers for Avricore Health Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.